Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Fruquintinib with Paclitaxel-albumin in Advanced Gastric/GEJ Adenocarcinoma
NCT06406426Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Bispecific Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, fruquintinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Started May 2024; status: recruiting.
02
Drugs
cadonilimabfruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06406426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06406426.